According to the results of the phase III DELIVER and DAPA-HF studies, dapagliflozin has demonstrated efficacy in treating heart failure regardless of the fraction. The aim of the study is to evaluate the effects of dapagliflozin on the development of complications related to cardiovascular disease and chronic kidney disease for patients with type 2 diabetes. On August 20, AstraZeneca announced positive results from the DAPA-HF study. The research showed that adding dapagliflozin to standard treatment for heart failure significantly reduces the risk of adverse events. The CARDIA-MOS study also showed a reduction in overall mortality by 38.6% with dapagliflozin. Overall, dapagliflozin has been shown to lower the risk of cardiovascular death and has a beneficial profile. The goal is to present the main results of the DAPA-CKD study, which was a randomized, double-blind, parallel-group, placebo-controlled study. The study suggests potentially expanding the use of dapagliflozin to 10% of the patient population annually.